Full interview with Gilead CEO on pricing for Covid-19 drug remdesivir

Gilead Sciences announced Monday the pricing for its coronavirus treatment remdesivir, saying it will cost $3,120 for a typical U.S. patient with commercial insurance. Gilead CEO Daniel O'Day joins "Squawk Box" to discuss.